Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLeguízamo Martínez, Lina María
dc.contributor.authorHurtado, Isabel
dc.contributor.authorSanfélix-Gimeno, Gabriel
dc.contributor.authorSanchez-Saez, Francisco
dc.contributor.authorBallarín, Elena
dc.contributor.authorSabaté, Mònica
dc.date.accessioned2025-10-21T11:15:22Z
dc.date.available2025-10-21T11:15:22Z
dc.date.issued2025-07-31
dc.identifier.citationLeguízamo-Martínez LM, Ballarin ME, Hurtado I, Sanfélix-Gimeno G, Sánchez-Sáez F, Sabaté M. Real-world adherence trajectories to direct oral anticoagulants in naive patients with atrial fibrillation in Spain. Front Pharmacol. 2025 Jul 31;16:1562620.
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/11351/13896
dc.descriptionAdherence trajectories; Atrial fibrillation; Direct oral anticoagulants
dc.description.abstractAims: This study aimed to identify adherence trajectories and associated factors in atrial fibrillation patients who initiated direct oral anticoagulant (DOAC) therapy, using population-based data from the Catalonia and Valencia regions in Spain during a 2-year follow-up. Methods and results: Group-based trajectory modelling (GBTM) was applied to assess adherence patterns in cohorts comprising 14,641 patients in Catalonia and 13,211 in Valencia. Adherence trajectories were categorised based on prescription data, revealing three main trajectories in Valencia and five in Catalonia. Most patients in Valencia demonstrated high adherence, whereas Catalonia showed more varied patterns, including early, gradual, and late declines. Factors associated with non-adherence included high co-insurance levels, alcohol use, and specific DOACs, such as dabigatran. Conclusion: Adherence trajectories differed between the two regions, with three identified in Valencia and five in Catalonia. Shared non-adherence patterns were observed across both cohorts, while Catalonia exhibited additional noncompliance trends. Key factors associated with non-adherence included socio-economic variables, clinical characteristics, and the type of DOAC prescribed. Understanding these patterns is essential for developing targeted intervention strategies to improve adherence and optimise treatment outcomes.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Pharmacology;16
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFibril·lació auricular - Tractament
dc.subjectAnticoagulants (Medicina) - Ús terapèutic
dc.subjectMedicació oral
dc.subjectPacients - Cooperació
dc.subject.meshMedication Adherence
dc.subject.meshAnticoagulants
dc.subject.mesh/therapeutic use
dc.subject.meshAdministration, Oral
dc.subject.meshAtrial Fibrillation
dc.subject.mesh/drug therapy
dc.titleReal-world adherence trajectories to direct oral anticoagulants in naive patients with atrial fibrillation in Spain
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fphar.2025.1562620
dc.subject.decsadhesión a la medicación
dc.subject.decsanticoagulantes
dc.subject.decs/uso terapéutico
dc.subject.decsadministración oral
dc.subject.decsfibrilación atrial
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.3389/fphar.2025.1562620
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Leguízamo-Martínez LM] Department of Clinical Pharmacology, Area Medicament, Hospital Clinic of Barcelona, Barcelona, Spain. Department of Clinical Pharmacology, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Ballarin ME] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Hurtado I, Sanfélix-Gimeno G] Health Services Research and Pharmacoepidemiology Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica (FISABIO), Valencia, Spain. Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud - RICAPPS, Barcelona, Spain. [Sánchez-Sáez F] Health Services Research and Pharmacoepidemiology Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica (FISABIO), Valencia, Spain. Red de Investigación en Cronicidad, Atención Primaria y Prevención y Promoción de la Salud - RICAPPS, Barcelona, Spain. Department of Applied Statistics and Operational Research, and Quality, Universitat Politècnica de València, Valencia, Spain. [Sabaté M] Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid40822488
dc.identifier.wos001549663600001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record